MedOncMD

To provide the information your oncologist is not telling you or doesn't have the time to!

  • Home
  • Magazine
  • Blog
    • The essentials
    • Art of Oncology
    • Prevention and Healthy Lifestyle
    • Research Advances
    • Navigation Corner
    • Video Library
  • Navigation Corner
  • Meet and Greet
    • About Dr Thomas
    • About Dr Landau
  • Ask MedOncMD?
  • Keep in Touch!

Replimune’s RP1: A New Hope for Advanced Melanoma Patients

For patients with advanced melanoma who have exhausted standard treatment options, new therapies offer much-needed hope. On November 21, 2024, Replimune Group, Inc. announced that its breakthrough oncolytic immunotherapy, RP1 (vusolimogene oderparepvec), in combination with nivolumab, received Breakthrough Therapy Designation from the FDA. The FDA also accepted a Biologics License Application (BLA) for RP1 under …

Read On »

FDA Accelerates Approval of Zanidatamab-hrii for HER2-Positive Biliary Tract Cancer

On November 20, 2024, the FDA granted accelerated approval to zanidatamab-hrii (Ziihera), a bispecific HER2-directed antibody, for the treatment of previously treated, unresectable, or metastatic HER2-positive biliary tract cancer (BTC). This decision brings new hope for patients battling this aggressive and hard-to-treat disease, offering a targeted option for a population with limited therapeutic choices. The …

Read On »

The Role of Electrolytes in Oncology: Vital for Diagnosis, Treatment, and Quality of Life

Electrolytes—essential minerals such as calcium, potassium, and magnesium—play a critical role in maintaining various physiological functions. In oncology, the importance of monitoring and managing electrolytes cannot be overstated. Electrolyte imbalances can not only signal the presence of malignancies but also influence the safety and efficacy of cancer treatments. This blog explores the significance of key …

Read On »

Reevaluating Radiation in Resectable Gastric Cancer: Insights from the TOPGEAR Trial

Radiation therapy has long been a cornerstone in the treatment of various cancers, including gastric cancer, particularly for locally advanced or high-risk cases. However, the evolving landscape of gastric cancer management has raised questions about the necessity of adding preoperative chemoradiotherapy to standard perioperative chemotherapy. The recently published TOPGEAR trial sheds new light on this …

Read On »

When Hepatic Tumors Are Rumors: A Case of Peliosis Hepatis Mimicking Malignancy

In the world of oncology, the old adage holds true: “When tumors are the rumors and cancer is possibly the answer, then tissue is the issue.” This highlights the critical role of biopsy in uncovering the true nature of suspicious lesions. Hepatic tumors, in particular, pose a diagnostic challenge because they encompass a broad spectrum …

Read On »

Innovative Advances in Bladder Cancer Treatment: Durvalumab Plus Chemotherapy in the NIAGARA Trial

Bladder cancer, particularly muscle-invasive bladder cancer (MIBC), poses significant treatment challenges due to its high recurrence rate and aggressive nature. Traditionally, neoadjuvant chemotherapy followed by surgery (radical cystectomy) has been the standard of care for cisplatin-eligible patients. However, researchers have been exploring ways to improve outcomes by incorporating immunotherapy into treatment. A recent phase 3 …

Read On »

New Horizons in Colon Cancer Treatment: Neoadjuvant Immunotherapy for Mismatch Repair–Deficient High Risk Stage II/III Colon Cancer

Colon cancer treatments have long relied on surgery, chemotherapy, and radiation. However, recent breakthroughs in immunotherapy, particularly for mismatch repair–deficient (dMMR) tumors, are reshaping how certain high-risk cancers are treated. A recent study published in The New England Journal of Medicine provides encouraging data on the effectiveness of neoadjuvant immunotherapy for patients with locally advanced dMMR colon …

Read On »

A Breakthrough in Treating IgG4-Related Disease: The Promise of Inebilizumab

IgG4-related disease (IgG4-RD) is a chronic, immune-mediated disorder that can affect multiple organs, causing inflammation, fibrosis, and long-term organ damage. I uncommonly see these patients as they often present as a retroperitoneal mass concerning for a connective tissue malignancy however biopsied proven IgG4 related non-malignant disease requiring immunosuppressant treatment which I often did as there …

Read On »

Advances in Hormone-Positive, HER2-Negative Breast Cancer: Inavolisib Plus Palbociclib and Fulvestrant Shows Promising Results for PIK3CA-Mutated Cases

For patients with a specific type of breast cancer—hormone receptor-positive, HER2-negative—that also carries a PIK3CA mutation, a new combination treatment shows promising results. The treatment combines inavolisib, a targeted therapy, with palbociclib and fulvestrant, helping to significantly slow disease progression compared to standard treatment. This combination not only targets multiple cancer growth pathways but also …

Read On »

E-Cigarettes vs. Smoking: Can Vaping Help Reduce the Risk of Lung Cancer?

Lung cancer remains one of the most common and deadly cancers worldwide. Smoking is responsible for approximately half of all lung cancer cases, making it the single most preventable cause of this disease. For individuals who have smoked for years, quitting can be difficult, and many turn to alternatives like electronic cigarettes (e-cigarettes) as a …

Read On »

  • Previous
  • Page 1
  • …
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • …
  • Page 23
  • Next

Recent Posts

  • The Story Behind the Logo: Building the Bridge, Stone by Stone
  • Remembering Dr. Craig Kitchens: The Legacy of a Great Physician
  • Six Months Later: Rediscovering Balance Through Locum Life and New Ventures
  • When Delay Becomes Harm: A Clinician’s Reflection on Timely Cancer Care
  • Understanding Disability in Oncology: A Clinician’s Perspective

Categories

  • Art of Oncology (78)
  • Current News (12)
  • Immunotherapy News (9)
  • Navigation Corner (6)
  • Prevention and Healthy Lifestyle (18)
  • Research Advances (108)
    • Clinical Trials (43)
    • Immunotherapy (29)
    • New Treatments and Therapies (42)
  • The essentials (41)
    • Radiology (4)
  • Travel Health (1)
  • Uncategorized (10)
  • Varied Cancer Perspectives (114)
    • Biliary tract cancer (3)
    • Bladder Cancer (3)
    • Breast Cancer (10)
    • Cervical Cancer (2)
    • CNS Cancers (1)
    • Colorectal cancer (13)
    • Esophageal Cancer (2)
    • Gastric cancer (6)
    • Hepatic Tumors (1)
    • Leiomyosarcoma (2)
    • Leukemia (2)
    • Lung Cancer (10)
    • Lymphoma (3)
    • Melanoma (28)
    • Multiple Myeloma (3)
    • Neuroendocrine cancer (2)
    • Ovarian Cancer (3)
    • Pancreatic Cancer (5)
    • Prostate Cancer (4)
    • Sarcoma (2)
    • Sickle Cell Disease (4)
    • Skin Cancer (7)
    • Thyroid cancer (1)
    • Urothelial Cancer (1)
  • Video (2)
  • Weekly Newsletter (6)

Get in touch!

  • Facebook
  • Instagram
  • TikTok
  • LinkedIn


Meet the authors

Dr. Sajeve Thomas
Dr Daniel Landau


Subscribe


  • Home
  • Magazine
  • Blog
    • The essentials
    • Art of Oncology
    • Prevention and Healthy Lifestyle
    • Research Advances
    • Navigation Corner
    • Video Library
  • Navigation Corner
  • Meet and Greet
    • About Dr Thomas
    • About Dr Landau
  • Ask MedOncMD?
  • Keep in Touch!
© 2025 MedOncMD. Minimal Theme by SPYR
✕
  • Home
  • Magazine
  • Blog
    • The essentials
    • Art of Oncology
    • Prevention and Healthy Lifestyle
    • Research Advances
    • Navigation Corner
    • Video Library
  • Navigation Corner
  • Meet and Greet
    • About Dr Thomas
    • About Dr Landau
  • Ask MedOncMD?
  • Keep in Touch!